Alogabat is a small molecule commercialized by F. Hoffmann-La Roche, with a leading Phase II program in Autism Spectrum Disorder (ASD). According to Globaldata, it is involved in 6 clinical trials, of which 3 were completed, and 3 are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Alogabat’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Alogabat is expected to reach an annual total of $10 mn by 2038 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Alogabat Overview
Alogabat (RG-7816, RO-7017773) is under development for the treatment of autism spectrum disorders and Angelman Syndrome. The drug candidate is administered through oral route as tablet, capsule. It acts by targeting GABRA5 receptor. The drug candidate is a new molecular entity (NME).
F. Hoffmann-La Roche Overview
F. Hoffmann-La Roche (Roche) is a biotechnology company that develops drugs and diagnostics to treat major diseases. It provides medicines for the treatment of cancer, other auto-immune diseases, central nervous system disorders, ophthalmological disorders, infectious diseases, and respiratory diseases. The company also offers in vitro diagnostics, tissue-based cancer diagnostics, and diabetes management solutions. Roche conducts research to identify novel methods to prevent, diagnose, and treat diseases. The company offers its products and services to hospitals, healthcare professionals, commercial laboratories, researchers, and pharmacists. Roche is headquartered in Basel, Switzerland.
The company reported revenues of (Swiss Francs) CHF58,716 million for the fiscal year ended December 2023 (FY2023), a decrease of 7.2% over FY2022. In FY2023, the company’s operating margin was 25.8%, compared to an operating margin of 27.5% in FY2022. In FY2023, the company recorded a net margin of 19.6%, compared to a net margin of 19.6% in FY2022.
For a complete picture of Alogabat’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.